Precision Medicine Tests
What Tests Does Myriad Oncology Offer?
BRACAnalysis CDx® is an FDA-approved test used to identify patients with germline BRCA1/2 mutations who may be eligible for certain targeted therapies. This test quickly and accurately provides results for patients with metastatic pancreatic cancer, metastatic breast cancer, ovarian cancer, and metastatic prostate cancer who may benefit from PARP inhibitor treatment.
The Myriad myRisk® Hereditary Cancer Test is a multi-gene panel that determines hereditary cancer risk associated with 8 cancer sites: breast, ovarian, colorectal, endometrial, melanoma, pancreatic, gastric, and prostate. Learn more here.
EndoPredict® is a tumor test designed for women with ER+/HER2-, early-stage, node-negative or node-positive breast cancer. The test combines the molecular score from the tumor with the tumor size and nodal status to provide individualized answers for three critical aspects of a breast cancer treatment plan.